Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono and Takeda reconsider matuzumab development

Merck Serono has announced it is considering whether to further develop its humanised monoclonal antibody drug matuzumab for metastatic colorectal cancer patients.

Merck Serono has announced it is considering whether to further develop its humanised monoclonal antibody drug matuzumab for metastatic colorectal cancer patients.

According to the company, a phase II trial investigating matuzumab in combination with irinotecan in patients with metastatic colorectal cancer (mCRC) who had already failed on multiple prior treatments, including irinotecan, has not met its predefined endpoint of activity.

Swtizerland-based Merck Serono is co-developing matuzumab with Japanese company Taked. According to a statement by Merck Serono, both companies share the view that the study results do not meet expectations.

The companies will continue to study the drug in other tumours including non-small cell lung cancer (NSCLC).

29th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics